BPG is committed to discovery and dissemination of knowledge
Basic Study
©Author(s) (or their employer(s)) 2026.
World J Gastrointest Surg. Feb 27, 2026; 18(2): 114286
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114286
Figure 5
Figure 5 Sensitivity of patient-derived tumor-like cell clusters to FOLFOX, FOLFIRI and FOLFOXIRI. A: Microscopic images of drug killing effects on patient-derived tumor-like cell clusters (PTCs); B: Inhibitory effects of FOLFOX, FOLFIRI and FOLFOXIRI on 54 PTCs. From top to bottom, the samples are represented sequentially from colorectal cancer (CRC)-1 to CRC-54. 0 represented PA = 0 (blue), 1.0 represented PA = 1.0 (red); C: The cases of strong killing, effective killing and ineffective killing on PTC models; D: The percentage of strong killing, effective killing and ineffective killing on PTC models. CRC: Colorectal cancer; PTC: Patient-derived tumor-like cell cluster.


Write to the Help Desk